SCHEDULE 13G: Orca Capital AG Discloses 9.7% Stake in Can-Fite BioPharma Ltd.
Beneficial Ownership Disclosure
Orca Capital AG has reported a 9.7% beneficial ownership stake in Can-Fite BioPharma Ltd., holding 375 million ordinary shares.
Summary
- Orca Capital AG, a German entity, has filed a Schedule 13G with the SEC, indicating beneficial ownership of Can-Fite BioPharma Ltd.'s ordinary shares.
- The filing reports that Orca Capital AG beneficially owns 375,000,000 ordinary shares of Can-Fite BioPharma Ltd.
- This ownership stake represents 9.7% of the total ordinary shares outstanding for Can-Fite BioPharma Ltd.
- The percentage calculation is based on an aggregate of 3,855,926,493 ordinary shares outstanding, which includes shares issued after the completion of the Issuer's registered offering as described in a Prospectus Supplement filed on April 15, 2025.
- Orca Capital AG holds sole voting power and sole dispositive power over all 375,000,000 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of a significant beneficial ownership stake. While not directly indicative of operational performance, a substantial investment by an institutional entity can be viewed as a neutral to slightly positive signal of investor confidence.
Positives
- Orca Capital AG, a German entity, has taken a significant 9.7% stake in Can-Fite BioPharma Ltd., which can be interpreted as a signal of confidence from an institutional investor.
Future Outlook
NA
Management Comments
- Orca Capital AG certified that the securities referred to were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This Schedule 13G filing indicates a significant institutional investment in the biotechnology/pharmaceutical sector, a common occurrence as investors seek opportunities in companies like Can-Fite BioPharma Ltd. The filing itself is a routine disclosure for investors crossing the 5% ownership threshold, providing transparency on major shareholders.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 04/14/2025 | Date of event which requires the filing of this statement (crossing the 5% beneficial ownership threshold). |
| 04/15/2025 | Date of the Issuer's Prospectus Supplement filing pursuant to Rule 424(b)(5), which describes a registered offering that impacted the total shares outstanding. |
| 04/16/2025 | Date the Schedule 13G was signed by Orca Capital AG. |
Keywords
Can-Fite BioPharma Ltd., Orca Capital AG, Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investment, SEC Filing, Biopharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.